The Immune System and Autoimmune Disease Explained

The immune system is the body's primary defense architecture against pathogens, but in autoimmune disease, this same system misidentifies healthy tissue as a threat and mounts a sustained attack against it. Understanding the boundary between protective immunity and pathological self-reactivity is foundational to rheumatology, a specialty defined by disorders where that boundary has failed. This page covers how the immune system is structured, how autoimmune mechanisms arise, which conditions result, and where clinical decision-making draws lines between immune-mediated and non-immune disease.

Definition and scope

An autoimmune disease is a condition in which the adaptive immune system generates responses—antibodies, cytotoxic T cells, or both—directed against the body's own antigens. The National Institute of Allergy and Infectious Diseases (NIAID) recognizes more than 80 clinically distinct autoimmune conditions, ranging from organ-specific disorders such as Hashimoto's thyroiditis to systemic diseases that affect connective tissue, joints, kidneys, skin, and the vascular system simultaneously.

In rheumatology, the diseases of greatest clinical relevance are those that target the musculoskeletal system and connective tissues. These include rheumatoid arthritis, lupus, scleroderma, Sjögren's syndrome, vasculitis, and ankylosing spondylitis, among others. Collectively, autoimmune conditions affect an estimated 23.5 million Americans, according to data referenced by NIAID, though some epidemiological analyses place the figure higher depending on case definition criteria.

The regulatory framework governing diagnosis and treatment of autoimmune diseases in the United States involves oversight by the U.S. Food and Drug Administration (FDA), which approves biologics, disease-modifying antirheumatic drugs (DMARDs), and JAK inhibitors used in immune-mediated disease management. Clinicians treating these conditions operate within standards published by the American College of Rheumatology (ACR), which issues classification criteria and clinical practice guidelines. For further detail on how regulation shapes clinical practice in this specialty, see Regulatory Context for Rheumatology.

How it works

The immune system operates across two interacting branches: innate immunity and adaptive immunity.

Innate immunity is the rapid, non-specific first response. It involves physical barriers (epithelial surfaces), pattern-recognition receptors that detect molecular signatures common to pathogens, phagocytic cells (neutrophils, macrophages), and inflammatory mediators including cytokines such as IL-1, IL-6, and TNF-α. This branch activates within minutes to hours and does not retain memory.

Adaptive immunity is slower but highly specific. It depends on two major cell types:

  1. B lymphocytes (B cells) — Mature into plasma cells that produce antibodies (immunoglobulins) targeted to specific antigens. In autoimmune disease, B cells may produce autoantibodies such as rheumatoid factor (RF), anti-CCP antibodies, anti-double-stranded DNA (anti-dsDNA), or anti-Ro/La antibodies.
  2. T lymphocytes (T cells) — CD4+ helper T cells regulate immune activation and differentiate into subsets (Th1, Th2, Th17, T-regulatory). CD8+ cytotoxic T cells destroy antigen-bearing cells. Th17 cells, which produce IL-17, are strongly implicated in the pathogenesis of psoriatic arthritis and ankylosing spondylitis.

Normal self-tolerance is maintained through two mechanisms: central tolerance, in which T and B cells reactive to self-antigens are eliminated during development in the thymus and bone marrow, and peripheral tolerance, which suppresses autoreactive cells that escape central deletion. Autoimmune disease occurs when both layers fail. Genetic susceptibility—particularly HLA (human leukocyte antigen) alleles—significantly modulates this risk. The HLA-B27 allele, for example, is present in approximately 90% of patients with ankylosing spondylitis, as documented by the National Library of Medicine/MedlinePlus.

Environmental triggers—viral infections, microbiome shifts, occupational exposures, hormonal changes—can initiate or accelerate autoreactivity in genetically predisposed individuals. The concept of molecular mimicry, in which pathogen-derived peptides share structural similarity with self-antigens, is one documented mechanism by which infection can breach tolerance.

Common scenarios

Autoimmune diseases present along a spectrum from organ-specific to systemic. The following classification reflects clinical and mechanistic groupings used in rheumatology practice:

Systemic autoimmune rheumatic diseases (SARDs):
- Systemic lupus erythematosus (SLE) — Characterized by anti-dsDNA and anti-Smith antibodies; affects kidneys, skin, joints, and the central nervous system.
- Rheumatoid arthritis (RA) — Driven by synovial inflammation; associated with RF and anti-CCP positivity in approximately 60–80% of cases (ACR RA Diagnosis Guidelines).
- Systemic sclerosis (scleroderma) — Autoimmunity triggers fibrosis and vascular injury.
- Sjögren's syndrome — Targets exocrine glands; linked to anti-Ro (SSA) and anti-La (SSB) antibodies.

Spondyloarthropathies:
- Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis share HLA-B27 associations and IL-17-mediated pathology.

Inflammatory myopathies:
- Polymyositis, dermatomyositis — T-cell and antibody-mediated attack on muscle tissue.

Vasculitides:
- Giant cell arteritis, granulomatosis with polyangiitis — Immune complex deposition and T-cell activation within vessel walls.

A clinical overview of the full specialty scope is available at the rheumatologyauthority.com index.

Decision boundaries

Distinguishing autoimmune disease from non-autoimmune conditions requires structured clinical reasoning because symptoms such as joint pain, fatigue, and inflammation are common to both categories.

Key differentiating criteria include:

  1. Autoantibody profile — Presence of disease-specific antibodies (anti-CCP, ANA, ANCA, anti-dsDNA) supports autoimmune etiology. A positive ANA alone is insufficient; ANA is detected in approximately 13% of healthy individuals at a 1:80 titer dilution, per data published in Arthritis & Rheumatology.
  2. Pattern of joint involvement — Symmetric small-joint polyarthritis suggests RA; asymmetric large-joint oligoarthritis suggests spondyloarthropathy; mono-articular acute inflammation suggests gout or septic arthritis.
  3. Systemic features — Serositis, nephritis, photosensitive rash, and oral ulcers raise probability of SLE; dry eyes and dry mouth with parotid swelling suggest Sjögren's.
  4. Inflammatory markers — Elevated ESR and CRP support inflammation but are non-specific. Normal inflammatory markers in the context of widespread pain and fatigue point toward fibromyalgia, a non-inflammatory condition.
  5. Imaging findings — Erosive change on X-ray or MRI bone marrow edema at sacroiliac joints support inflammatory, not degenerative, disease.

The distinction between inflammatory and non-inflammatory arthritis carries direct treatment implications. Autoimmune-driven disease typically requires immune-modifying therapy (DMARDs, biologics, JAK inhibitors, or corticosteroids), whereas non-inflammatory conditions such as osteoarthritis are managed with analgesics, physical therapy, and structural interventions.

Importantly, autoimmune conditions can coexist. Overlap syndromes—where a patient meets criteria for two or more autoimmune diagnoses simultaneously—are documented in clinical literature and require individualized treatment plans. Rheumatologists also distinguish primary autoimmune disease from drug-induced lupus, paraneoplastic syndromes, and infection-triggered reactive arthritis, each carrying distinct management pathways.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)